Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
-$0.27 today
- Market cap
- $430.84M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
Volume 1.67M
Average 1.21M
PHAT Income Before Tax
Profit after all operating and non-operating items but before income tax.
Phathom Pharmaceuticals, Inc.NASDAQ: PHAT
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$30.37M, compared with -$94.32M a year earlier. Trailing-twelve-month income before tax was -$157.3M.
Context
- Income before tax amounted to 126.3% of revenue in FY2025, down 478.7 pp from a year earlier.
- Income before tax grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -$30.37M or moves back toward the trailing-twelve-month quarterly average of -$39.33M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (221.25M) USD
- Year-over-year change
- +33.8%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (221.25M) | +33.8% |
| FY2024 | 2024-12-31 | (334.33M) | -65.8% |
| FY2023 | 2023-12-31 | (201.59M) | -2.0% |
| FY2022 | 2022-12-31 | (197.72M) | -37.4% |
| FY2021 | 2021-12-31 | (143.88M) | — |
Income Before Tax vs competitors
How PHAT compares with its peers on the latest reported figures
- PHAT's LTM Mar 2026 income before tax of -$157.3M is the lowest of the 2 companies compared; the peer median is -$57.94M.
- Its year-over-year change of +54.5% is the highest of 2, against a peer median of -9.8%.
- Income before tax amounts to 76.8% of revenue for PHAT, versus a peer median of 13.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$57.94M | -9.8% | — | 13.5% | |
| LTM Mar 2026 | -$157.3M | +54.5% | — | 76.8% | |
| Peer median (excluding PHAT) | -$57.94M | -9.8% | — | 13.5% | |
Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 682K | 55.25M | 175.11M |
| Cost of Revenue | 521K | 620K | 167K | 7.97M | 22.6M |
| Gross Profit | (521K) | (620K) | 515K | 47.28M | 152.51M |
| Gross Margin | — | — | 75.5% | 85.6% | 87.1% |
| Research & Development | 72.34M | 71.44M | 49.9M | 34.08M | 32.78M |
| Selling, General & Admin | 62.22M | 100.38M | 117.93M | 290.66M | 279.72M |
| Operating Expenses | 134.56M | 171.82M | 167.83M | 324.75M | 312.5M |
| Depreciation & Amortization | 521K | 620K | 575K | 795K | 633K |
| EBITDA | (136.57M) | (169.8M) | (159.05M) | (261.52M) | (152.5M) |
| EBITDA Margin | — | — | -23321.0% | -473.3% | -87.1% |
| Operating Income | (135.08M) | (172.44M) | (167.31M) | (277.47M) | (159.99M) |
| Operating Margin | — | — | -24532.6% | -502.2% | -91.4% |
| Interest Income | 41K | 2.13M | 7.88M | 15.16M | 7.04M |
| Interest Expense | 6.79M | 27.31M | 41.97M | 72.01M | 68.12M |
| Other Income / Expenses | (8.8M) | (25.28M) | (34.28M) | (56.86M) | (61.26M) |
| Income Before Tax | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Pre-Tax Margin | — | — | -29558.9% | -605.1% | -126.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Net Margin | — | — | -29558.9% | -605.1% | -126.3% |
| EPS (Basic) | (4.00) | (5.70) | (3.93) | (5.29) | (3.03) |
| EPS (Diluted) | (4.00) | (5.70) | (3.93) | (5.29) | (3.03) |
| Weighted Avg Shares | 37M | 39.12M | 51.29M | 63.18M | 72.92M |
| Weighted Avg Shares (Diluted) | 37M | 39.12M | 51.29M | 63.18M | 72.92M |
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
Intrinsic Alpha fair value
Locked
Current Price
$5.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.